BioSpace News Archive

RenovaCare announced the closing of its previously announced registered direct offering of 915,000 shares of its common stock at a an offering price of $2.50 per share and its concurrent private placement of common stock purchase warrants (the “Warrants” to purchase 915,000 shares of common stock.

Veracyte, Inc. announced that data presented at the 87th Annual Meeting of the American Thyroid Association (ATA) being held October 18-22 in Victoria, BC, Canada.

Spero plans for a rapid development approach with SPR994.

The FDA has been working closely with dozens of pharmaceutical and medical device companies to help these important facilities get back online.

M3 Biotechnology is a clinical stage company with a novel platform of disease-modifying regenerative therapies particularly relevant to neurodegenerative diseases, with a focus on Alzheimer’s. M3’s lead asset, NDX-1017, modifies growth factor systems and is advanced as a first-in-class, disease-modifying treatment with the potential to restore lost connections between brain cells, turning degeneration into regeneration.

The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on its clinical and development activities.

The event will be on October 20-24, 2017, at the Washington Convention Center in Washington, D.C.

The EMA has designated ofranergene obadenovec (VB-111) as an ‘orphan medicinal product’ for the treatment of ovarian cancer.

The Orphan Drug designation allows RedHill to benefit from various development incentives to develop MESUPRON for this indication.

ANGLE plc, a world-leading liquid biopsy company, announces that its AGM will be held at 2:00pm on Tuesday 31 October 2017 at ANGLE plc, 10 Nugent Road, the Surrey Research Park, Guildford, GU2 7AF.